Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases

Alimentary Pharmacology and Therapeutics

Volumn 46, Issue 11-12, 2017, Pages 1037-1053

  Mitrev, N ^a   Vande Casteele, N ^a   Seow, C H ^a   Andrews, J M ^a   Connor, S J ^a   Moore, G T ^a   Barclay, M ^a   Begun, J ^a   Bryant, R ^a   Chan, W ^a   Corte, C ^a   Ghaly, S ^a   Lemberg, D A ^a   Kariyawasam, V ^a   Lewindon, P ^a   Martin, J ^a   Mountifield, R ^a   Radford Smith, G ^a   Slobodian, P ^a   Sparrow, M ^a   Toong, C ^a   van Langenberg, D ^a   Ward, M G ^a   Leong, R W ^a   more..

^a NONE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BIOLOGICAL MARKER; CALGRANULIN; CORTICOSTEROID; DRUG ANTIBODY; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ANTIBODY; USTEKINUMAB; VEDOLIZUMAB; GASTROINTESTINAL AGENT;

ADVERSE DRUG REACTION; ANTIBODY DETECTION; ANTIBODY TITER; CLINICAL DECISION MAKING; CONSENSUS; COST CONTROL; CROHN DISEASE; DIAGNOSTIC ACCURACY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INTENSIFICATION; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INFUSION; DRUG INFUSION REACTION; DRUG MONITORING; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FECES LEVEL; FISTULA; HEALING; HUMAN; IMMUNOGENICITY; INFLAMMATORY BOWEL DISEASE; MINIMUM PLASMA CONCENTRATION; MUCOSAL HEALING; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; REVIEW; RISK REDUCTION; SYMPTOM; SYSTEMATIC REVIEW; AUSTRALIA; BLOOD; DELPHI STUDY; PROCEDURES; TREATMENT FAILURE;

ADALIMUMAB; AUSTRALIA; DELPHI TECHNIQUE; DRUG MONITORING; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; TREATMENT FAILURE;

EID: 85031325690     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.14368     Document Type: Review

References (185)

1. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
2. Sandborn WJ, vanAssche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257-265. e1-3.
3. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644-659, quiz 660.
4. Sprakes MB, Ford AC, Warren L, Greer D, Hamlin J. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. J Crohns Colitis. 2012;6:143-153.
5. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2016;375:1946-1960.
6. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699-710.
7. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369:711-721.
8. Roda G, Jharap B, Neeraj N, Colombel JF. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7:e135.
9. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 2011;33:987-995.
10. Osterman MT, Roblin X, Glover SC, et al. Association of vedolizumab drug concentrations at or before week 6 with remission at week 14 in moderately to severely active ulcerative colitis patients from GEMINI 1. Gastroenterology. 2016;150:S105.
11. Rosario M, Abhyankar B, Sankoh S, Dirks N, Lasch K, Sandborn W. Relationship between vedolizumab pharmacokinetics and endoscopic outcomes in patients with ulcerative colitis. ECCO; 2015.
12. Adedokun OJ, Xu Z, Gasink C, et al. Sa1934 Pharmacokinetics and exposure-response relationships of Ustekinumab during IV induction and SC maintenance treatment of patients with Crohn's disease with Ustekinumab: results from the UNITI-1, UNITI-2, and IM-UNITI studies. Gastroenterology. 2016;150:S408.
13. Battat R, Kopylov U, Bessissow T, et al. 696 association of Ustekinumab trough concentrations with clinical, biochemical and endoscopic outcomes. Gastroenterology. 2016;150:S144-S145.
14. Brooks KW. Delphi technique: expanding applications. N Central Assoc Q. 1979;54:377-385.
15. Custer RL, Scarcella JA, Stewart BR. The modified Delphi technique: a rotational modification. J Voc Tech Educ. 1999;15:1-10.
16. Hsu C, Sandford BA. The Delphi technique: making sense of consensus. Pract Assess Res Eval. 2007;12:1-8.
17. Ludwig B. Predicting the future: have you considered using the Delphi methodology? J Extens. 1997;35:1-4.
18. Cyphert FR, Gant WL. The Delphi technique: a case study. Phi Delta Kappan. 1971;52:272-273.
19. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ. 1995;311:376-380.
20. Chen JH, Andrews JM, Kariyawasam V, et al. Review article: acute severe ulcerative colitis – evidence-based consensus statements. Aliment Pharmacol Ther. 2016;44:127-144.
21. Merlin T, Weston A, Tooher R, et al. NHMRC additional levels of evidence and grades for recommendations for developers of guidelines. Canberra, ACT: Australian Government; 2009.
22. Melmed GY, Irving PM, Jones J, et al. Appropriateness of testing for anti-tumor necrosis factor agent and antibody concentrations, and interpretation of results. Clin Gastroenterol Hepatol. 2016;14:1302-1309.
23. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
24. Baert F, Drobne D, Gils A, et al. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. Clin Gastroenterol Hepatol. 2014;12:1474-1481 e2; quiz e91.
25. Steenholdt C, Bendtzen K, Brynskov J, Ainsworth MA. Optimizing treatment with TNF inhibitors in inflammatory bowel disease by monitoring drug levels and antidrug antibodies. Inflamm Bowel Dis. 2016;22:1999-2015.
26. Singh N, Rosenthal CJ, Melmed GY, et al. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:1708-1713.
27. Baert F, Kondragunta V, Lockton S, et al. Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial. Gut. 2015;65:1126-1131.
28. Ding NS, Hart A, de Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease – algorithm for practical management. Aliment Pharmacol Ther. 2016;43:30-51.
29. Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014;63:1721-1727.
30. Amin A, Prosser C, Kroeker K, et al. Using infliximab trough levels and fecal calprotectin levels together to guide clinical decisions has the potential to improve outcomes in inflammatory bowel disease patients on maintenance infliximab therapy. Gastroenterology. 2016;150:S422.
31. Brandse JF, Strik AS, Mould D, et al. Insufficient infliximab exposure predisposes to immunogenicity and enhanced clearance of infliximab in IBD. Gastroenterology. 2016;150 (4, Suppl. 1):S144.
32. Ungar B, Chowers Y, Yavzori M, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut. 2014;63:1258-1264.
33. Ben-Horin S. Immunogenicity of anti-TNFs – letting the immune system be the judge. In: IXTEND 2016. Sydney: 2016.
34. Steenholdt C, Frederiksen MT, Bendtzen K, Ainsworth MA, Thomsen OO, Brynskov J. Time course and clinical implications of development of antibodies against adalimumab in patients with inflammatory bowel disease. J Clin Gastroenterol. 2015;50:483-489.
35. Vande Casteele N, Compernolle G, Ballet V, et al. Results on the optimisation phase of the prospective controlled trough level adapted infliximab treatment (TAXIT) trial, 2012.
36. Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148:1320-1329 e3.
37. Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63:919-927.
38. Steenholdt C, Brynskov J, Thomsen OO, et al. Individualized therapy is a long-term cost-effective method compared to dose intensification in Crohn's disease patients failing infliximab. Dig Dis Sci. 2015;60:2762-2770.
39. Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol. 2015;13:522-530 e2.
40. Roblin X, Rinaudo M, Del Tedesco E, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol. 2014;109:1250-1256.
41. Chiu YL, Rubin DT, Vermeire S, et al. Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Inflamm Bowel Dis. 2013;19:1112-1122.
42. Papamichael K, van Stappen T, Vande Casteele N, et al. Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2016;14:543-549.
43. Steenholdt C, Brynskov J, Thomsen OO, et al. Implications of infliximab treatment failure and influence of personalized treatment on patient-reported health-related quality of life and productivity outcomes in Crohn's disease. J Crohns Colitis. 2015;9:1032-1042.
44. Armuzzi A, Felice C. IBD: infliximab dose optimization in IBD-proactive or reactive? Nat Rev Gastroenterol Hepatol. 2014;11:706-708.
45. O'Toole A, Moss AC. Optimizing biologic agents in ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep. 2015;17:32.
46. Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn WJ, Cheifetz AS. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis. 2014;20:1996-2003.
47. Mitrev N, Leong RW. Therapeutic drug monitoring of anti-tumour necrosis factor-alpha agents in inflammatory bowel disease. Expert Opin Drug Saf. 2017;16:303-317.
48. D'Haens G, Vermeire S, Lambrecht G, et al. OP029 Drug-concentration versus symptom-driven dose adaptation of Infliximab in patients with active Crohn's disease: a prospective, randomised, multicentre trial (Tailorix). ECCO; 2016.
49. Papamichael K, Chachu KA, Vajravelu RK, et al. Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab. Clin Gastroenterol Hepatol. 2017;15:1580-1588.
50. Ben-Horin S, Chowers Y, Ungar B, et al. Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal. Aliment Pharmacol Ther. 2015;42:356-364.
51. Flamant M, Roblin X. Could therapeutic drug monitoring of anti-TNF-alpha be useful to consider a de-escalation of treatment? Expert Opin Biol Ther. 2015;15:1657-1660.
52. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142:63-70 e5; quiz e31.
53. Papamichael K, Vande Casteele N, Gils A, et al. Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission. Clin Gastroenterol Hepatol. 2015;13:1103-1110.
54. Gisbert JP, Marin AC, Chaparro M. The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2016;111:632-647.
55. Chauvin A, Le Thuaut A, Belhassan M, et al. Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: a retrospective study. Dig Liver Dis. 2014;46:695-700.
56. Hlavaty T, Krajcovicova A, Letkovsky J, et al. Relapse rates of inflammatory bowel disease patients in deep and clinical remission after discontinuing anti-tumor necrosis factor alpha therapy. Bratisl Lek Listy. 2016;117:205-211.
57. Papamichael K, Vermeire S. Withdrawal of anti-tumour necrosis factor alpha therapy in inflammatory bowel disease. World J Gastroenterol. 2015;21:4773-4778.
58. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324-1338.
59. Walsh AJ, Bryant RV, Travis SP. Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol. 2016;13:567-579.
60. Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut. 2014;63:88-95.
61. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105:162-169.
62. Dalal SR, Cohen RD. What to do when biologic agents are not working in inflammatory bowel disease patients. Gastroenterol Hepatol. 2015;11:657-665.
63. Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:1133-1139.
64. Strik AS, Bots SJ, D'Haens G, Lowenberg M. Optimization of anti-TNF therapy in patients with inflammatory bowel disease. Expert Rev Clin Pharmacol. 2016;9:429-439.
65. Menees SB, Powell C, Kurlander J, Goel A, Chey WD. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110:444-454.
66. Quigley EM. Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye? Therap Adv Gastroenterol. 2016;9:199-212.
67. Barratt SM, Leeds JS, Robinson K, Lobo AJ, McAlindon ME, Sanders DS. Prodromal irritable bowel syndrome may be responsible for delays in diagnosis in patients presenting with unrecognized Crohn's disease and celiac disease, but not ulcerative colitis. Dig Dis Sci. 2011;56:3270-3275.
68. Barratt SM, Leeds JS, Robinson K, et al. Reflux and irritable bowel syndrome are negative predictors of quality of life in coeliac disease and inflammatory bowel disease. Eur J Gastro Hepatol. 2011;23:159-165.
69. Berrill JW, Green JT, Hood K, Campbell AK. Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity. Aliment Pharmacol Ther. 2013;38:44-51.
70. Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2012;107:1474-1482.
71. Jelsness-Jorgensen LP, Bernklev T, Moum B. Fatigue and disease-related worries among inflammatory bowel disease patients in remission; is it a reflection of coexisting IBS-like symptoms? A short report. J Psychosom Res. 2012;73:469-472.
72. Jelsness-Jorgensen LP, Bernklev T, Moum B. Calprotectin is a useful tool in distinguishing coexisting irritable bowel-like symptoms from that of occult inflammation among inflammatory bowel disease patients in remission. Gastroenterol Res Pract. 2013;2013:620707.
73. Jonefjall B, Strid H, Ohman L, Svedlund J, Bergstedt A, Simren M. Characterization of IBS-like symptoms in patients with ulcerative colitis in clinical remission. Neurogastroenterol Motil. 2013;25:756-e578.
74. Keohane J, O'Mahony C, O'Mahony L, O'Mahony S, Quigley EM, Shanahan F. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol. 2010;105:1788, 1789–1794; quiz 1795.
75. Chang J, Leong RW, Wasinger V, Ip M, Yang M, Giang Phan T. Impaired intestinal permeability contributes to ongoing bowel symptoms in patients with inflammatory bowel disease and mucosal healing. Gastroenterology. 2017;153:723-731.
76. Wong SH, Tang W, Wu JC, Ng SC. Clostridium difficile infections in inflammatory bowel disease patients is associated with increased use of immunosuppressants and higher rates of colectomy: results from a population-based cohort. Digestive Diseases Week; 2016.
77. Lee HS, Park SH, Kim SH, et al. Risk factors and clinical outcomes associated with cytomegalovirus colitis in patients with acute severe ulcerative colitis. Inflamm Bowel Dis. 2016;22:912-918.
78. Louis E, El Ghoul Z, Vermeire S, et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther. 2004;19:511-519.
79. Louis EJ, Watier HE, Schreiber S, et al. Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study. Pharmacogenet Genomics. 2006;16:911-914.
80. Pierik M, Vermeire S, Steen KV, et al. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther. 2004;20:303-310.
81. Vande Casteele N, Gils A. Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: adding value to current practice. J Clin Pharmacol. 2015;55(Suppl. 3):S39-S50.
82. Siegel CA, Melmed GY. Predicting response to anti-TNF agents for the treatment of Crohn's disease. Therap Adv Gastroenterol. 2009;2:245-251.
83. Chowers Y, Sturm A, Sans M, et al. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. J Crohns Colitis. 2010;4:367-376.
84. Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE, Williams RO. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med. 2008;205:2491-2497.
85. Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2009;68:209-215.
86. Cleynen I, Van Moerkercke W, Juergens M, et al. Anti-TNF induced cutaneous lesions in IBD patients: characterization and search for predisposing factors. Gut. 2010;59(S3):A1.
87. Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol. 2012;9:496-503.
88. Billiet T, Cleynen I, Ferrante M, Van Assche G, Gils A, Vermeire S. A variable number of tandem repeat polymorphism in the promotor region of the neonatal FC receptor affects anti-TNF serum levels in IBD. Digestive Diseases Week; 2016; San Diego, CA, 2016.
89. Lallemand C, Kavrochorianou N, Steenholdt C, et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFalpha antagonists. J Immunol Methods. 2011;373:229-239.
90. Rojas JR, Taylor RP, Cunningham MR, et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther. 2005;313:578-585.
91. Brandse JF, van den Brink GR, Wildenberg ME, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015;149:350-355 e2.
92. Altwegg R, Vincent T. TNF blocking therapies and immunomonitoring in patients with inflammatory bowel disease. Mediators Inflamm. 2014;2014:172821.
93. Dotan I, Ron Y, Yanai H, et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis. 2014;20:2247-2259.
94. Ungar B, Mazor Y, Weisshof R, et al. Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. Aliment Pharmacol Ther. 2016;43:1293-1299.
95. Noertersheuser PA, Eckert D, Sharma S, et al. Factors affecting adalimumab pharmacokinetics in adult patients with moderate to severe CD. Gastroenterology. 2013;144:S230.
96. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
97. Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:444-447.
98. Ungar B, Yavzori M, Fudim E, et al. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. Digestive Diseases Week 2016, San Diego, CA, 2016.
99. Papamichael K, Gils A, Rutgeerts P, et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015;21:182-197.
100. Takeuchi T, Miyasaka N, Tatsuki Y, et al. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:1208-1215.
101. Yarur AJ, Jain A, Sussman DA, et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut. 2016;65:249-255.
102. Leclerc M, Marotte H, Paul S, et al. Persistence of antibodies to infliximab for more than two months strongly predicts loss of response to infliximab in inflammatory bowel diseases. DDW. Chicago, IL, 2014.
103. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009;137:1628-1640.
104. Minar P, Saeed SA, Afreen M, Kim MO, Denson LA. Practical use of infliximab concentration monitoring in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2016;62:715-722.
105. Viola F, Civitelli F, Di Nardo G, et al. Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease. Am J Gastroenterol. 2009;104:2566-2571.
106. Ungar B, Levy I, Yavne Y, et al. Optimizing anti-TNF-alpha therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2016;14:550-557. e2.
107. Vande Casteele N, Khanna R, Levesque BG, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut. 2015;64:1539-1545.
108. Yarur AJ, Rubin DT. Therapeutic drug monitoring of anti-tumor necrosis factor agents in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21:1709-1718.
109. Yamada A, Sono K, Hosoe N, Takada N, Suzuki Y. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF. Inflamm Bowel Dis. 2010;16:1898-1904.
110. Eser A, Primas C, Reinisch W. Drug monitoring of biologics in inflammatory bowel disease. Curr Opin Gastroenterol. 2013;29:391-396.
111. Ordas I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012;91:635-646.
112. Ternant D, Aubourg A, Magdelaine-Beuzelin C, et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit. 2008;30:523-529.
113. Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46:645-660.
114. Buurman DJ, Maurer JM, Keizer RJ, Kosterink JG, Dijkstra G. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice. Aliment Pharmacol Ther. 2015;42:529-539.
115. Fasanmade AA, Adedokun OJ, Ford J, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol. 2009;65:1211-1228.
116. Ternant D, Ducourau E, Fuzibet P, et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015;79:286-297.
117. Ward MG, Thwaites PA, Beswick L, et al. Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease. Aliment Pharmacol Ther. 2017;45:1135-1145.
118. Stewart MJ, Dubinsky M, Morganstern B, et al. Sa1965 the steady-state pharmacokinetics of adalimumab: do we need to drink from the “Trough”? Gastroenterology. 2016;150:S418-S419.
119. Baumgart DC, Grittner U, Steingraber A, Azzaro M, Philipp S. Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients. Inflamm Bowel Dis. 2011;17:2512-2520.
120. Department of Human Services. Ulcerative colitis. Australia: Australian Government, 2016.
121. Department of Human Services. Crohn's disease – adult patient. Australia: Australian Government, 2016.
122. Colombel JF, Sandborn WJ, Allez M, et al. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014;12:423-431. e1.
123. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:96-109. e1.
124. Bader L, Solberg SM, Kaada SH, et al. Assays for infliximab drug levels and antibodies: a matter of scales and categories. Scand J Immunol. 2017;86:165-170.
125. Steenholdt C, Ainsworth MA, Tovey M, et al. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease. Ther Drug Monit. 2013;35:530-538.
126. Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Ainsworth MA. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial. Am J Gastroenterol. 2014;109:1055-1064.
127. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12:205-217.
128. Enciso IP, Paredes LF, Sanchez-Ramon S, et al. Comparison of four assay kits for measuring infliximab trough levels and antibodies to infliximab in patients with inflammatory bowel disease. DDW, San Diego, CA; 2016.
129. Guiotto C, Daperno M, Frigerio F, et al. Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease. Dig Liver Dis. 2016;48:138-143.
130. Lee MW, Connor S, Ng W, Toong CM. Comparison of infliximab drug measurement across three commercially available ELISA kits. Pathology. 2016;48:608-612.
131. Malickova K, Duricova D, Bortlik M, et al. Serum trough infliximab levels: a comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease. Biologicals. 2016; 44: 33-36.
132. Schmitz EM, van de Kerkhof D, Hamann D, et al. Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits. Clinical Chemistry and Laboratory Medicine: CCLM/FESCC 2015.
133. van Bezooijen JS, Koch BC, Doorn MV, Prens EP, Gelder TV, Schreurs MW. A comparison of three assays to quantify infliximab, adalimumab and etanercept serum concentrations. Ther Drug Monit. 2016;38:432-438.
134. Adedokun OJ, Sandborn WJ, Feagan BG, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014;147:1296-1307 e5.
135. Bortlik M, Duricova D, Malickova K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J Crohns Colitis. 2013;7:736-743.
136. Paul S, Del Tedesco E, Marotte H, et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2013;19:2568-2576.
137. Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Ainsworth MA. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol. 2011;46:310-318.
138. Moore C, Corbett G, Moss AC. Systematic review and meta-analysis: serum infliximab levels during maintenance therapy and outcomes in inflammatory bowel disease. J Crohns Colitis. 2016;10:619-625.
139. Echarri A, Ferreiro R, Fraga-Iriso R, et al. Sa1264 drug trough levels and primary nonresponse to antiTNF therapy in moderate-severe Crohn disease. Results of the optimiza study. Gastroenterology. 2014;146 (Suppl. 1):S-247.
140. Feagan BG, Singh S, Lockton S, et al. 565 novel infliximab (IFX) and antibody-to-infliximab (ATI) assays are predictive of disease activity in patients with Crohn's disease (CD). Gastroenterology. 2012;142(5, Suppl. 1):S-114.
141. Lamblin C, Aubourg A, Ternant D, Picon L, Lecomte T, Paintaud G. P334. Concentration–effect relationship of infliximab in Crohn's disease: results of a cohort study. J Crohns Colitis. 2012;6:S142-S143.
142. Levesque BG, Greenberg GR, Zou G, et al. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. Aliment Pharmacol Ther. 2014;39:1126-1135.
143. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1248-1254.
144. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59:49-54.
145. Yarur A, Kanagala V, Stein D, et al. 514 Higher infliximab trough levels are associated with a higher rate of perianal fistula healing in patients with Crohn's disease. Gastroenterology. 2016;150:S105-S106.
146. Ben-Bassat O, Romanova A, Iacono A, Irwin SP, Greenberg GR. Association of serum infliximab and antibodies to infliximab to long-term clinical outcome and mucosal healing in Crohn's disease. Gastroenterology. 2013;144:S775.
147. Drobne D, Bossuyt PJ, Breynaert C, et al. Crohn's disease: infliximab trough levels and CRP during infliximab-immunomodulator combination treatment are associated with clinical outcome after immunomodulator withdrawal. Gastroenterology. 2011;140(5, Suppl. 1):S-62.
148. Huang VW, Prosser C, Kroeker KI, et al. Knowledge of fecal calprotectin and infliximab trough levels alters clinical decision-making for IBD outpatients on maintenance infliximab therapy. Inflamm Bowel Dis. 2015;21:1359-1367.
149. Warman A, Straathof JW, Derijks LJ. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study. Eur J Gastro Hepatol. 2015;27:242-248.
150. Drobne D, Kurent T, Rajar P, et al. High infliximab trough levels are associated with better control of inflammation in IBD. Digestive Diseases Week, San Diego, CA, 2016.
151. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134:1861-1868.
152. Hibi T, Sakuraba A, Watanabe M, et al. Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease. Inflamm Bowel Dis. 2012;18:1480-1487.
153. Imaeda H, Takahashi K, Fujimoto T, et al. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease. J Gastroenterol. 2014;49:100-109.
154. Mazor Y, Almog R, Kopylov U, et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. Aliment Pharmacol Ther. 2014;40:620-628.
155. Mostafa NM, Eckert D, Pradhan RS, Mensing S, Robinson AM, Sandborn WJ. P333 Exposure-efficacy relationship (ER) for adalimumab during induction phase of treatment of adult patients with moderate to severe ulcerative colitis (UC). U Eur Gastroenterol J. 2013;1:A221-A222.
156. Roblin X, Marotte H, Rinaudo M, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12:80-84 e2.
157. Sharma S, Eckert D, Hyams JS, et al. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study. Inflamm Bowel Dis. 2015;21:783-792.
158. Velayos FS, Sheibani S, Lockton S, et al. 490 prevalence of antibodies to adalimumab (ATA) and correlation between ata and low serum drug concentration on crp and clinical symptoms in a prospective sample of IBD patients. Gastroenterology. 2013;144:S-91.
159. Yarur AJ, Deshpande AR, Sussman DA, et al. Serum adalimumab levels and antibodies correlate with endoscopic intestinal inflammation and inflammatory markers in patients with inflammatory bowel disease. Gastroenterology. 2013;144:S774-S775.
160. Yarur AJ, Jain A, Hauenstein SI, et al. Higher Adalimumab levels are associated with histologic and endoscopic remission in patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2016;22:409-415.
161. Chaparro M, de Barreiro-Acosta M, Echarri A, et al. Correlation between anti-TNF serum levels and mucosal healing (MH) in inflammatory bowel disease (IBD) patient. Digestive Diseases Week, San Diego, CA, 2016.
162. Menting SP, Coussens E, Pouw MF, et al. Developing a therapeutic range of adalimumab serum concentrations in management of psoriasis: a step toward personalized treatment. JAMA Dermatol. 2015;151:616-622.
163. Pouw MF, Krieckaert CL, Nurmohamed MT, et al. Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis. 2015;74:513-518.
164. Yarur AJ, Kanagala V, Stein DJ, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease. Aliment Pharmacol Ther. 2017;45:933-940.
165. Mitrev N, Karijawasam V, Leong RW. Infliximab trough cut-off for perianal Crohn's disease: another piece of the therapeutic drug monitoring-guided infliximab dosing puzzle. Aliment Pharmacol Ther. 2017;45:1279-1280.
166. Kosmac M, Avcin T, Toplak N, Simonini G, Cimaz R, Curin Serbec V. Exploring the binding sites of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab. Pediatr Res. 2011;69:243-248.
167. van der Laken CJ, Voskuyl AE, Roos JC, et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis. 2007;66:253-256.
168. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013;108:40-47; quiz 48.
169. Vande Casteele N, Feagan BG, Gils A, et al. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep. 2014;16:378.
170. Paul S, Moreau AC, Del Tedesco E, et al. Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20:1288-1295.
171. Swoger JM, Levesque BG. Editorial: drug monitoring targets for optimising adalimumab in Crohn's disease. Aliment Pharmacol Ther. 2014;40:854-855.
172. Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology. 2007;46:1828-1834.
173. Steenholdt C, Brynskov J, Bendtzen K. Letter: persistence of anti-infliximab antibodies after discontinuation of infliximab in patients with IBD. Aliment Pharmacol Ther. 2012;36:499-500; author reply 501.
174. Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013;108:962-971.
175. Steenholdt C, Al-khalaf M, Brynskov J, Bendtzen K, Thomsen OO, Ainsworth MA. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2209-2217.
176. Vaughn BP, Sandborn WJ, Cheifetz AS. Biologic concentration testing in inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:1435-1442.
177. Wang SL, Ohrmund L, Hauenstein S, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods. 2012;382:177-188.
178. Scott FI, Lichtenstein GR. Therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease. Curr Treat Opt Gastroenterol. 2014;12:59-75.
179. Balsanek J, Willrich MAV, Murray DL, Snyder M. Sa1268 clinical development of an electrochemiluminescent immunoassay to measure antibodies-to-infliximab. Gastroenterology. 2014;146:S248.
180. Van Stappen T, Brouwers E, Vermeire S, Gils A. Validation of a sample pretreatment protocol to convert a drug-sensitive into a drug-tolerant anti-infliximab antibody immunoassay. Drug Test Anal. 2016;9:243-247.
181. Steenholdt C, Bendtzen K, Brynskov J, et al. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease. J Crohns Colitis. 2015;9:238-245.
182. Van Stappen T, Vande Casteele N, Van Assche G, Ferrante M, Vermeire S, Gils A. Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial. Gut. 2017; https://doi.org/10.1136/gutjnl-2016-313071 [Epub ahead of print].
183. Williet N, Boschetti G, Fovet M, et al. Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases with need for additional doses within 6 months. Clin Gastroenterol Hepatol. 2016; https://doi.org/10.1016/j.cgh.2016.11.023. [Epub ahead of print].
184. Rosario M, Dirks NL, Gastonguay MR, et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther. 2015;42:188-202.
185. Menting SP, van den Reek JM, Baerveldt EM, et al. The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting. Br J Dermatol. 2015;173:855-857.